Table 2.
Subset analyses evaluating the association between COVID-19 vaccine response (anti-SARS-CoV-2 spike protein IgG) after two doses of COVID-19 vaccine with control group and immunocompromised condition (20 studies)*.
| Subset | Number of Studies Included | Pooled Odds Ratio, M-H, Random, comparing Control Group with Immunocompromised Group (95% CI) | I2 test for heterogeneity |
|---|---|---|---|
| Anti-SARS-CoV-2 Spike protein IgG | 20 | 58.18 (21.61, 156.61) | 71% |
| Neutralizing antibodies | 3 | 181.92 (22.76, 1453.93) | 55% |
| Anti-SARS-CoV-2 Spike protein IgG in control group compared with solid organ transplant patients | 8 | 232.35 (66.98, 806.03) | 35% |
| Anti-SARS-CoV-2 Spike protein IgG in control group compared with patients with malignant diseases | 6 | 42.00 (11.68, 151.03) | 47% |
| Anti-SARS-CoV-2 Spike protein IgG in control group compared with patients with inflammatory rheumatic diseases | 3 | 19.06 (5.00, 72.62) | 0% |
| Studies with 19–23 of 28 points (D&B, Good) | 13 | 36.35 (10.59, 124.77) | 73% |
| Studies with 14–18 of 28 points (D&B, Good) | 7 | 136.80 (31.97, 585.29) | 54% |
CI=Confidence Interval; D&B=Downs & Black score; M-H=Mantel-Haenszel; Random=Random-effects method.
*Reasons for not including the other 13 studies in the meta-analysis: there are no raw numbers to perform the COVID-19 vaccine response (produced anti-SARS-CoV-2 spike protein IgG) after two doses of COVID-19 vaccine for immunocompromised patients.